Zobrazeno 1 - 10
of 68
pro vyhledávání: '"R. Angelo de Claro"'
Autor:
Xiajing Gong, Meng Hu, Jinzhong Liu, Geoffrey Kim, James Xu, Amy McKee, Todd Palmby, R. Angelo de Claro, Liang Zhao
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-9 (2022)
Small molecule kinase inhibitors (SMKIs) are being approved at a fast pace under expedited programs for anticancer treatment. Here, the authors employ a machine-learning model to examine the relationships between kinase targets and adverse events in
Externí odkaz:
https://doaj.org/article/0acfd12fa2c4416da16ad933f8db2dd9
Autor:
Nadia Howlader, Elad Sharon, Manami Bhattacharya, Lori A. Ehrlich, Nicholas C. Richardson, Nicole J. Gormley, R. Angelo de Claro, Amy E. Wood, Angela B. Mariotto, Kathleen A. Cronin
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. :OF1-OF4
Introduction: Molecularly targeted therapies such as tyrosine kinase inhibitors (TKI) are effective treatments for B-cell receptor (BCR)-ABL–bearing leukemias. We evaluated the impact of TKIs on historical chronic myeloid leukemia (CML) mortality t
Autor:
Mikkael A. Sekeres, Nina Kim, Amy E. DeZern, Kelly J. Norsworthy, Jacqueline S. Garcia, R. Angelo de Claro, Marc R. Theoret, Emily Y. Jen, Lori A. Ehrlich, Amer M. Zeidan, Rami S. Komrokji
Publikováno v:
Clinical Cancer Research. :OF1-OF7
Myelodysplastic syndromes (MDS) have historically been challenging diseases for drug development due to their biology, preclinical modeling, and the affected patient population. In April 2022, the FDA convened a panel of regulators and academic exper
Autor:
Kathleen A. Cronin, Angela B. Mariotto, Amy E. Wood, R. Angelo de Claro, Nicole J. Gormley, Nicholas C. Richardson, Lori A. Ehrlich, Manami Bhattacharya, Elad Sharon, Nadia Howlader
Supplementary Figure 1: Trends in Mortality by Leukemia Subtypes and Race Ethnicity. Total US 1992-2018. Results are shown for mortality trends for CML (panel A), ALL (panel B), and CLL (panel C), 1992-2018. For each panel, we show age-adjusted morta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dbb286b4d5ecabda426756d34cb6f14
https://doi.org/10.1158/1055-9965.22743779.v1
https://doi.org/10.1158/1055-9965.22743779.v1
Autor:
Kathleen A. Cronin, Angela B. Mariotto, Amy E. Wood, R. Angelo de Claro, Nicole J. Gormley, Nicholas C. Richardson, Lori A. Ehrlich, Manami Bhattacharya, Elad Sharon, Nadia Howlader
Introduction:Molecularly targeted therapies such as tyrosine kinase inhibitors (TKI) are effective treatments for B-cell receptor (BCR)-ABL–bearing leukemias. We evaluated the impact of TKIs on historical chronic myeloid leukemia (CML) mortality tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1608fc95c4bc943532fef93efcac9e5
https://doi.org/10.1158/1055-9965.c.6628385
https://doi.org/10.1158/1055-9965.c.6628385
Autor:
Lauren T. Hotaki, Anu Shrestha, Monica P. Bennett, Ivelisse L. Valdes, Sso H. Lee, Yinghua Wang, Dianne Spillman, Tina MacAulay, Melissa Hunt, Julie Gervais, Maral Mafi, Vincent Panetta, Yee Hoo Looi, Michael Shum, Eiman Atiek, Ricarda Meincke, Ulrich-Peter Rohr, Denize Ainbinder, Anat Boehm-Cagan, Osnat Luxenburg, Mateus Rodrigues Cerqueira, Laila Sofia Mouawad, Maria Fernanda Reis e Silva Thees, Krishna Prasad, R. Angelo de Claro
Publikováno v:
Therapeutic Innovation & Regulatory Science.
Autor:
Richard Pazdur, Ann T. Farrell, Edvardas Kaminskas, Robert Justice, Robert C. Kane, Janice Brown, Debasis Ghosh, Li Shan Hsieh, Nitin Mehrotra, Dhananjay Marathe, Julie Bullock, Stacy Shord, Haleh Saber, Ramadevi Gudi, Natalie Simpson, Lei Nie, Kyung Lee, R. Angelo de Claro, Donna Przepiorka, Barry W. Miller
Supplementary Table 1: Preferred Terms included in grouped terms
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89c3d8e513d6abb1ac67db7a05ddd5a4
https://doi.org/10.1158/1078-0432.22461069
https://doi.org/10.1158/1078-0432.22461069
Autor:
R. Angelo De Claro, Marc R. Theoret, Richard Pazdur, Kirsten B. Goldberg, Adam N. Maung, Sherita McLamore, Anamitro Banerjee, Rakhi Shah, Djelila Mezaache, Paresma Patel, Yuching Yang, Lian Ma, Olanrewaju O. Okusanya, Jonathon Vallejo, Soumya Mitra, Ramadevi Gudi, Ying-Hong Wang, Ruo-Jing Li, Alexei Ionan, Robert Q. Le, Donna Przepiorka
On July 16, 2021, the FDA approved belumosudil, a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic GvHD (cGvHD) after failure of at least two prior lines of systemic therapy. Approval was based on the results of Stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cf5ad9b338cb810d274cde6114ea10c
https://doi.org/10.1158/1078-0432.c.6532340
https://doi.org/10.1158/1078-0432.c.6532340
Autor:
Richard Pazdur, Ann T. Farrell, R. Angelo De Claro, Kirsten B. Goldberg, Olanrewaju O. Okusanya, Wentao Fu, Donna Przepiorka, Ramadevi Gudi, Hisham Qosa, Qing Xu, Yaping Wang, Kelly J. Norsworthy, E. Dianne Pulte
Supplementary tables and figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81d5a0bd44acecd80b9cbc54dd71f147
https://doi.org/10.1158/1078-0432.22480182.v1
https://doi.org/10.1158/1078-0432.22480182.v1
Autor:
Richard Pazdur, Ann T. Farrell, R. Angelo De Claro, Kirsten B. Goldberg, Olanrewaju O. Okusanya, Wentao Fu, Donna Przepiorka, Ramadevi Gudi, Hisham Qosa, Qing Xu, Yaping Wang, Kelly J. Norsworthy, E. Dianne Pulte
On November 28, 2018, the FDA approved gilteritinib (Xospata; Astellas), a small-molecule FMS-like tyrosine kinase 3 (FLT3) inhibitor, for treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation as detected by an FDA-approved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39fb5856f55a7a14d432509c0d36c0b0
https://doi.org/10.1158/1078-0432.c.6530388
https://doi.org/10.1158/1078-0432.c.6530388